Long-Acting Injectables at AAAP 37th Annual Meeting and Scientific Symposium

7 sessions on long-acting injectables · November 12–15, 2026, Memphis, TN. Compare long-acting injectables at other meetings →

Friday, November 13

15:30–17:00 · Oral abstract
Long-Acting Injectable Antipsychotics in Serious Mental Illness with Co-Occurring Substance Use: A Retrospective Cohort Study
Kathryn Renard
Cohort study of long-acting injectable antipsychotic use in patients with serious mental illness and substance use.
Serious Mental Illness · Substance Use Disorders

From Methadone 200 mg/day to Brixadi: Successful Inpatient Transition Using Low-Dose Buprenorphine Induction for Persistent QTc Prolongation — Michelle Williamson
From Opioid Avoidance to Kratom Dependence: Treatment of Kratom Use Disorder with Long-Acting Injectable Buprenorphine — Alejandro Lopez
Incidence of Precipitated Withdrawal Following Rapid Initiation of Weekly and Monthly Extended-Release Injectable Buprenorphine in Adults With Moderate-to-Severe Opioid Use Disorder Not Currently Receiving Buprenorphine: A Study Protocol — Natalie Budilovsky-Kelley
Substance Use Burden and Psychiatric Readmission following Long-Acting Injectable Antipsychotic Initiation — Angelo Chaia
Substance Use Patterns and Clinical Complexity as Predictors of Psychiatric Readmission among Inpatients Receiving Long-Acting Injectable Antipsychotics — Kathryn Renard
48-Hour Transdermal Buprenorphine Induction to Initiate Extended-Release Buprenorphine for the Management of Opioid Use Disorder in an Outpatient setting: A Retrospective Case Series — Alaa Al Hawamdeh